ISRCTN73768226已完成未知
A two part study examining the analgesic efficacy and tolerability of three fixed-dose combinations of ibuprofen plus acetaminophen for adults with dental pain following third molar extraction: A double-blind, parallel-group, placebo-controlled, randomised, repeat dose trial with two-centre factorial design
Reckitt Benckiser Healthcare (UK)0 个研究点目标入组 735 人开始时间: 2010年6月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 735
研究概览
简要总结
2010 results in https://doi.org/10.1016/j.clinthera.2010.06.002 (added 20/02/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age: Subjects at least 16 years of age were eligible to participate
- •2. Sex: Both males and females were eligible for entry
- •3. Primary Diagnosis: At least three impacted third molars (two of which must have been mandibular impacted molars) indicated for removal. Both mandibular impactions must have required bone removal, and there must have been a total score of 9 or greater on the impaction grading scale for the three or four impacted third molar
- •4. Baseline pain intensity (PI): Subjects must have been experiencing moderate to severe postoperative pain based on the Pain Intensity Categorical Rating Scale and have a PI Visual Analogue Scale (VAS) score of 50mm or greater on the 100mm within 6 hours of completion of surgery, but more than 3 hours after the last administration of fentanyl
- •5. Subjects who gave written informed consent. Subjects who were 16 or 17 years of age also required their parents or legal guardian to provide written informed consent in addition to their written assent
排除标准
- •1. Those who had participated in a clinical trial in the previous 12 weeks. Twelve weeks calculated from the time of last dosing in the prior trial to time of anticipated first dosing in this trial.
- •2. A current history of significant disease deemed by the Investigator to render the subject unsuitable for inclusion
- •3. An ongoing painful condition other than that associated with the current third molar surgery
- •4. Any ongoing condition that may have interfered with the absorption, distribution, metabolism or excretion of the study medication
- •5. A history of allergy or intolerance (including angioedema, urticaria, bronchospasm and rhinitis) related to the treatment with ibuprofen, acetaminophen, aspirin, other NSAIDs or any other medication used in this study, including anaesthetics and antibiotics that may have been required on the day of the surgery (Day 1) or the formulation constituents of the study medications
- •6. A history of frequent peptic ulcers, duodenal ulcers or gastrointestinal (GI) bleeding
- •7. A history of frequent dyspepsia, heartburn or indigestion
- •8. A history of migraine headaches within the past year
- •9. A history of psychotic illness, attempted suicide or neurosis
- •10. Those unable to refrain from smoking during their stay in the research centre
- •11. A positive history of drug or alcohol abuse within the past six months
- •12. Those who were taking any concomitant medication that might have confounded assessments of pain relief (PAR), such as: psychotropic drugs, antidepressants, sedative-hypnotics (other than those permitted for conscious sedation), or other analgesics taken within five times of their elimination half lives. Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs) were permitted if the subject had been on a stable dose for at least four weeks prior to visit 1 (screening).
- •13. Those previously randomised into this study
- •14. Subjects who had received ant analgesic, anti-inflammatory drug, sedative-hypnotic, or caffeine containing food or drink from midnight the night prior to surgery and during the entire 80 hours post-dose assessment period, except for the study medication, perioperative sedative, antibiotics or permitted anaesthetics. The following anaesthetics were permitted lidocaine with epinephrine, nitrous oxide, diazepam (Valium), methohexitol (Brevital) and fentanyl. The following antibiotics were permitted: penicillin, macrolide antibiotics, clindamycin and topical tetracycline gelfoam.
- •15. Those who were unable, in the opinion of the investigator, to comply fully with the study requirements.
- •16. Those with abnormal liver function tests at screening
- •17. A history of epileptic seizures
研究者
相似试验
尚未招募
不适用
Comparison of two different techniques of ultrasound guided blocks for pain relief in laparoscopic gall bladder removalCTRI/2019/07/020414nil
已完成
3 期
A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to OsteoarthritisPainOsteoarthritisNCT00833794Labopharm Inc.1,028
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With OsteoarthritisOsteoarthritis, HipOsteoarthritis, KneeNCT00411164Alza Corporation, DE, USA990
尚未招募
不适用
Study to evaluate analgesic efficacy between USG -guided transverse fascia plane block and conventional ilioinguinal/ iliohypogastric nerve blockCTRI/2021/01/030775Super Speciality Paediatric Hospital and Post Graduate Teaching Institute
尚未招募
不适用
Prospective comparison of the analgesia effect according to the volume of local anesthetics on pericapsular nerve group (PENG) block using ultrasound in patients undergoing total hip arthroplastyKCT0006721The Catholic University of Korea, Eunpyeong St. Mary's Hospital68